Physician profile
John Timothy Cope
NPI 1609878974
$4,612.07
in general payments reported to CMS, 2019-2025
32 companies · $925 in 2025
The $925 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $205 · 2021: $595 · 2022: $953 · 2023: $399 · 2024: $616 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.97 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,796.65 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $388.05 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $354.90 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $295.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $206.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $181.88 | 2019-2025 | |
| Abbvie INC. | $178.13 | 2021-2023 | Synthroid, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.15 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $103.65 | 2020-2021 | |
| Medtronic, INC. | $99.51 | 2025 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $92.68 | 2021-2025 | Shingrix, Arexvy, Boostrix |
| Abbott Laboratories | $87.43 | 2022-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $85.83 | 2020-2022 | |
| Exact Sciences Corporation | $85.37 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $58.63 | 2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $53.22 | 2019-2022 | |
| Corcept Therapeutics | $45.41 | 2023-2025 | Korlym |
| Inspire Medical Systems, INC. | $42.84 | 2025 | Inspire |
| Dexcom, INC. | $39.79 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.93 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $29.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.24 | 2024 | Glassia |
| Xeris Pharmaceuticals, INC. | $24.51 | 2025 | Gvoke Hypopen |
| Genentech USA, INC. | $19.06 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.74 | 2022 | |
| Seqirus USA INC | $14.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.58 | 2019 | |
| Amgen INC. | $13.37 | 2022 | |
| Boston Scientific Corporation | $13.15 | 2024 | Watchman Access System |
| Adlon Therapeutics L.P. | $13.06 | 2020 | |
| Sanofi Pasteur INC. | $12.09 | 2019 | |
| Cequr Corporation | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.